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obtained clinical trials data for all drugs represented first line therapy for MDD. For
this reason, response rates were down-adjusted to reflect their use as a second-line
therapy, with each response rate being multiplied by a factor obtained from the
STAR*D- trial. Since response rates were reported at a constant rate in clinical
trials, they were converted into “weekly probabilities” of response. Patients enter-
ing second-line monotherapy were not differentiated by switch or add-on.
QuetiapineXR(150mg) was compared with venlafaxineXR(150mg),
escitalopram(10mg) and bupropionXL(300mg), which are considered to be the most
relevant monotherapy comparators in Turkey. One-way sensitivity analyses were
conducted on key model parameters to evaluate the robustness of the model.
RESULTS: The response rates at any time over 52 weeks were 22.5% for quetiap-
ineXR, venlafaxineXR 17.8%, escitalopram 12.6% and bupropionXL 10.7%. In terms
of incremental cost per additional second-line responder, quetiapineXR was found
to be dominant (more effective and less costly) versus venlafaxineXR (-353.55€) and
quetiapineXR was cost-effective (more effective and more costly) versus escitalo-
pram (1785.43€) and bupropionXL (652.90€). The cost per responder of quetiap-
ineXR(48.85€) was less than venlafaxineXR(62.68€), escitalopram(73.20€) and
bupropionXL(95.52€). CONCLUSIONS: This exploratory analysis demonstrated that
in patients with MDD who have failed on previous antidepressant therapy, quetia-
pineXR 150mg as monotherapy was found to be cost-effective compared to escita-
lopram and bupropionXL, in terms of cost per responder, and was dominant when
compared to venlafaxineXR, demonstrating higher efficacy at lower costs.
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OBJECTIVES: In schizophrenia, medication adherence is critical to achieve better
patient outcomes and to avoid relapses, which are responsible for a significant
proportion of total healthcare costs for this chronic illness. The aim of this study
was to assess the cost-effectiveness of olanzapine long-acting injection (OLAI)
compared with risperidone long-acting injection (RLAI) in patients with schizo-
phrenia in Spain. METHODS: A discrete event simulation (DES) model was devel-
oped from a Spanish healthcare system perspective to estimate clinical and eco-
nomic outcomes for patients with schizophrenia over a five year period. Patients
who had earlier responded to oral medication and have a history of relapse due to
adherence problems were considered. These patients faced the option to be treated
with either OLAI or RLAI. In the absence of a head-to-head clinical trial, discontin-
uation and relapse rates were obtained from an indirect comparison of open-label
studies. The model accounted for age, gender, risks of relapse and discontinuation,
relapse management, hospitalization, treatment switching and adverse events.
Direct medical costs (year 2011) and outcomes including relapse avoided, life years
(LYs), and quality-adjusted life years (QALYs) were discounted at a rate of 3%.
RESULTS: When comparing RLAI and OLAI, the model predicts that OLAI would
decrease 5-year costs by €2940, and results in a QALY and LY gain of 0.07 and 0.04,
respectively. Patients on OLAI had fewer relapses compared to RLAI (1.39 vs. 1.82)
and fewer discontinuations (1.22 vs. 1.71). Sensitivity analysis indicated that the
study was robust and conclusions were largely unaffected by changes in a wide
range of parameters. CONCLUSIONS: The present evaluation results in OLAI being
dominant over RLAI, meaning that OLAI represents a more effective and less costly
alternative compared to RLAI in the treatment of patients with schizophrenia in
the Spanish setting.
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OBJECTIVES: To determine the cost-effectiveness of agomelatine for major depres-
sion in adults. METHODS: A hypothetical cohort was simulated from a discrete
event simulation (DES) model developed to describe the course of disease in indi-
viduals. Model inputs included Thai data on disease parameters and costs while
impact measures are derived from systematic reviews and meta-analyses of the
international literature. The costs for treatment of adverse events of these drugs,
insomnia and sexual dysfunction, were taken into account in the model. Antide-
pressant drugs were analyzed for treatment of episodes (12-24 weeks) plus a con-
tinuation phase (6-9 months) and for maintenance treatment over 2 years of follow
up. Results are presented as Thai Baht cost (THB) per quality adjusted life year
(QALY) gained, compared to a matrix comparators (50 % venlafaxine and 50%
escitalopram). RESULTS: Preliminary results show that daily costs for average dose
of agomelatine (25 mg), escitalopram (10 mg) and venlafaxine (150 mg) are 52, 60, 98
THB, respectively. Total cost of agomelatine is 52,000 THB and total cost of matrix
comparator is 76,000 THB. Health benefit measures of agomelatine and the matrix
comparator are almost the same at 2,500 QALY gained. Agomelatine is considered
a cost-effective intervention with an ICER of 400,000 (95% uncertainty range:
410,000- 390,000) THB per QALY gained. The ICER is less than three times Gross
Domestic Product (GDP) per capita in Thailand of 420,000 THB. CONCLUSIONS:
Agomelatine is the most cost-effective treatment option for episodic continuation
and maintenance treatment of major depression when compared with venlaflax-
ine and escitalopram. As recommended by the World Health Organization (WHO)
for cost-effectiveness health intervention, agomelatine is an affordable option for
treatment of major depressive episodes in Thailand.
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OBJECTIVES: Paliperidone ER Extended Release OROS (ER) is a relatively new atyp-
ical antipsychotic for the treatment of schizophrenia. The objective is, based on a
previously published model, to analyze the clinical and economic effects of Pali-
peridone ER in Spain compared to olanzapine oral and aripiprazole. METHODS: An
existing discrete event simulation model was adapted to reflect the treatment of
schizophrenia in Spain in terms of costs, resource use and treatment patterns.
Inputs for the model were derived from clinical trial data, literature search, data-
base analysis, and interviews with local clinical experts. The time horizon is five
years and Spanish discount rates were applied. Outputs included direct medical
costs and Quality Adjusted Life-Years (QALYs). Sensitivity analyses were con-
ducted to assess the uncertainty surrounding incremental outcomes and to iden-
tify model drivers, by performing probabilistic sensitivity analysis (PSA) and ordi-
nary least squares analysis (OLSA). RESULTS: The mean (95% CI) incremental
QALYs compared to olanzapine is 0.033 [-0.14, 0.30] and compared to aripiprazole
0.029 [-0.11,0.30]. The corresponding mean incremental costs (95% CI) are -€ 1,425
[-€ 10,247, €3,084] and -€ 759 [-€ 10,479, € 3,404] respectively. Based on the PSA, the
probability that paliperidone ER is cost-saving and improves QALYs compared to
olanzapine and aripiprazole is 76% and 72% respectively. Paliperidone ER was es-
timated to have 80% and 81% probability of being cost effective compared to olan-
zapine at a willingness to pay of €20,000 and €30,000 and 73% and 74% compared to
aripiprazole respectively. OLSA identified drug acquisition costs, side effects and
risk of relapse to be major model drivers. CONCLUSIONS: Based on differences in
drug acquisition costs, side effects and risk of relapse, the model predicts that in
Spain paliperidone ER provides QALY gains and cost savings compared with oral
olanzapine and aripiprazole with a probability of 76% and 72% respectively.
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OBJECTIVES: To evaluate cost-utility of amisulpride compared with first genera-
tion antipsychotics (FGA) in treatment of schizophrenia in adult patients in Poland.
METHODS: A decision-tree model was used to estimate utilities and costs of treat-
ment of amisulpride therapy in comparison to FGA (antipsychotics, management
of main antipsychotics’ adverse events - extrapyramidal symptoms’ (EPS) and
health care costs). The FGA group included the following drugs: haloperidol, pera-
zine and flupenthixol. Analysis was performed from the National Health Fund
(NHF) perspective with a time horizon of 1 year. The range of possible events in the
model included: therapy discontinuation (regardless of reason), EPS occurrence,
schizophrenia relapse and suicide. Range of events was assumed to be the same for
amisulpride and FGA but probabilities of those events varied between antipsychot-
ics. Based on systematic review of RCTs amisulpride is more effective than FGA in
terms of compliance rate and in reduction of both the risk of relapse and occur-
rence of EPS. A probabilistic sensitivity analysis was performed to estimate the
probability that amisulpride is cost effective in Polish conditions (threshold about
100,000 PLN/QALY). RESULTS: From the NHF perspective amisulpride compared
with FGA was more effective (	QALY  0.004) and it was cheaper (comparing to
flupenthixol) or cost-effective (ICUR1 079/QALY PLN and ICUR31 810/QALY PLN
in comparison to haloperidol and perazine, respectively). The calculated probabil-
ity that amisulpride is more effective than any of FGA was 100%, while the proba-
bility that it is also cost-effective varied between 68% for perazine to 83% for
flupenthixol. CONCLUSIONS: Treatment of schizophrenia with amisulpride is a
cost-effective option in comparison to FGA in Poland. The obtained difference in
QALY is very small, but reduced risk of relapse and necessity of hospitalization due
to better effectiveness of amisulpride and reduced occurrence of EPS results in a
better cost benefit outcome for amisulpride compared to FGA.
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OBJECTIVES: Paliperidone palmitate long-acting injection (PP-LAI) has recently
been approved in Europe for treatment of schizophrenia as an alternative to olan-
zapine pamoate (OLZ-LAI). Their relative cost-effectiveness has not yet been ade-
quately assessed. The purpose was to compare costs and outcomes of these two
LAIs in treating schizophrenia in Norway. METHODS: A previously validated and
published decision analytic model estimating costs and outcomes of treatment
schizophrenia over a 1-year time horizon was adapted to simulate clinical practice
patterns in Norway. Drugs of interest were PP-LAI and OLZ-LAI. Clinical inputs
were derived from the literature and experts, and costs from standard lists. Clinical
outcomes included days in remission, hospitalizations, hospitalized days, and
quality-adjusted life-years (QALYs). Costs were derived from the public health care
provider perspective and reported in 2010 Norwegian kroner (NOK; €17.8 kroner,
USD$15.4 kroner). The pharmacoeconomic outcome was the incremental cost
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